Supportive Care and Monitoring during Deep Sedation – Pharmacy & Acute Care University

1. Mechanical Ventilation

Deep sedation often accompanies mechanical ventilation to ensure patient-ventilator synchrony and facilitate lung-protective strategies in critically ill patients.

Indications for Deep Sedation

Severe Acute Respiratory Distress Syndrome (ARDS) with PaO₂/FiO₂ < 150 mmHg despite optimized PEEP/FiO₂
Persistent tachypnea (Respiratory Rate >35/min) with significant accessory muscle use
Severe metabolic acidosis requiring controlled ventilation
Elevated intracranial pressure

Sedation and Synchrony Strategies

Sedation Targets: Initiate at a Richmond Agitation-Sedation Scale (RASS) score of –4 to –5 for severe ARDS or intracranial hypertension. Titrate to a lighter target of RASS –2 to 0 once the primary insult stabilizes.
Synchrony Strategies: Utilize adaptive support ventilation or proportional modes to improve patient comfort. Monitor for lung protection by maintaining tidal volumes of 4–8 mL/kg of ideal body weight and plateau pressures below 30 cm H₂O.

Weaning Protocol

A structured weaning protocol is essential. Once the patient is stable with a RASS target of –2 to 0, proceed with daily Spontaneous Awakening Trials (SATs) to assess neurologic function, followed by a Spontaneous Breathing Trial (SBT) to evaluate readiness for extubation.

Clinical Pearl: Coordinated Weaning +

Early, coordinated sedation breaks paired with spontaneous breathing trials have been shown to shorten the duration of mechanical ventilation and ICU length of stay without increasing the risk of adverse events like self-extubation.

2. Hemodynamic Support Strategies

Many sedative agents can cause vasodilation and negative inotropy, leading to hypotension. A strategy of balanced fluid resuscitation and tailored vasopressor use is critical to maintain end-organ perfusion.

Fluid Resuscitation

Balanced crystalloids are the first-line fluid choice. Fluid responsiveness should be assessed dynamically using methods like a passive leg raise (PLR) or stroke volume variation (SVV) from an arterial line to avoid fluid overload.

Vasopressor Therapy

First-line: Norepinephrine, initiated at 0.01–0.1 μg/kg/min and titrated to maintain a mean arterial pressure (MAP) of ≥65 mmHg.
Second-line: Add vasopressin at a fixed dose of 0.03 units/min for refractory hypotension or if norepinephrine requirements exceed 0.25 μg/kg/min to reduce catecholamine exposure.

Hemodynamic Monitoring

Continuous monitoring is essential. An arterial line provides real-time MAP and allows for assessment of pulse pressure variation. Serial lactate measurements should be trended, with a goal of >10% clearance over 2 hours indicating successful resuscitation.

Clinical Pearl: Early Arterial Line Placement +

Place an arterial catheter early in any patient requiring deep sedation. Non-invasive blood pressure cuffs can be inaccurate in low-flow states, potentially masking significant hypotension and delaying necessary interventions.

3. Prevention of ICU-Related Complications

Immobility from deep sedation increases the risk of iatrogenic complications. Prophylactic measures should be implemented to reduce venous thromboembolism (VTE), stress ulcers, and device-associated infections.

A. Venous Thromboembolism (VTE) Prophylaxis

Pharmacologic: Unless a high bleeding risk exists, use enoxaparin 40 mg subcutaneously once daily or unfractionated heparin 5,000 units subcutaneously every 8–12 hours. Consider anti-Xa level monitoring in patients with obesity or renal dysfunction.
Mechanical: Use intermittent pneumatic compression devices when pharmacologic anticoagulation is contraindicated. Encourage active and passive range-of-motion exercises as sedation lightens.

B. Stress-Related Mucosal Bleeding Prophylaxis

Prophylaxis is indicated for patients with coagulopathy, those on mechanical ventilation for more than 48 hours, or those requiring vasopressor support.

Common Agents for Stress Ulcer Prophylaxis
Agent	Standard Dose	Route	Clinical Notes
Pantoprazole (PPI)	40 mg once daily	IV or Enteral	Preferred agent due to efficacy. May be associated with a small increased risk of pneumonia.
Ranitidine (H₂RA)	50 mg every 8 hours	IV	Alternative if PPI is contraindicated. Tachyphylaxis can occur after several days.

C. Catheter-Associated Infection Prevention

Central Line Bundle: Adhere strictly to hand hygiene, maximal sterile barrier precautions during insertion, chlorhexidine skin preparation, and daily review of line necessity.
Urinary Catheter Protocol: Check for necessity daily. Use securement devices to prevent movement and maintain a closed drainage system at all times.

Clinical Pearl: Bundle Compliance Audits +

Regular (e.g., monthly) audits of bundle compliance with transparent feedback to clinical staff have been shown to reduce central line–associated bloodstream infection (CLABSI) rates by over 50%.

4. Management of Iatrogenic Complications

Vigilant detection and prompt management are required to address common complications induced by sedation, including hypotension, respiratory depression, and delirium.

A. Sedation-Induced Hypotension

Reduce the sedative infusion rate by 25% increments.
Reassess volume status and perfusion markers.
If MAP remains <65 mmHg after a fluid challenge, initiate or increase vasopressor support.

B. Respiratory Depression

Monitoring: Use continuous capnography (EtCO₂) and pulse oximetry for all deeply sedated patients, especially those receiving opioid infusions.
Reversal: For opioid-induced respiratory depression, administer naloxone 0.04 mg IV and titrate every 2 minutes as needed to restore adequate ventilation while attempting to preserve analgesia.

C. Delirium Management

A stepwise approach is recommended, prioritizing non-pharmacologic interventions.

Figure 1: Stepwise Approach to Delirium Management. Non-pharmacologic strategies are the foundation of care. Pharmacologic agents are reserved for cases of severe agitation that pose a safety risk.

Clinical Pitfall: Pharmacologic Delirium Treatment +

Routine pharmacologic treatment of hypoactive delirium is not recommended and may prolong ICU stay. Antipsychotics like haloperidol can prolong the QTc interval and should be used at the lowest effective dose for the shortest duration possible, primarily for hyperactive delirium causing severe agitation.

5. Multidisciplinary Goals-of-Care Conversations

The intensity and duration of deep sedation must be aligned with the patient’s values and overall prognosis. This requires regular, documented discussions involving all relevant stakeholders.

Stakeholders: Key participants include the primary critical care team (physicians, nurses, pharmacists, respiratory therapists), palliative care specialists, ethics consultants, and most importantly, the patient or their designated surrogate decision-maker.
Documentation: Conversations should be clearly documented, outlining advance directives, agreed-upon sedation ceilings (e.g., “do not exceed RASS –4”), and the duration of therapeutic trials of deep sedation.
Re-evaluation Triggers: Establish clear triggers for re-evaluating the goals of care, such as the development of a new organ failure, failure to improve after a predefined sedation trial, or a change in the patient’s code status.

Clinical Pearl: Embedding Goals in Daily Rounds +

Explicitly stating the daily sedation goal (e.g., “Today’s RASS target is -1 to 0”) during multidisciplinary rounds ensures consistent team alignment and helps prevent “sedation creep,” where deep sedation is continued unnecessarily out of habit.

6. Standardized Monitoring Protocols

Structured and consistent monitoring ensures the safety and efficacy of sedation and all associated supportive care measures, allowing for timely adjustments.

Sedation Depth: Assess RASS (or RASS-PAL for palliative patients) every 2–4 hours and after any dose change. The goal should be clearly defined, with a default target of RASS –2 to 0 once deep sedation is no longer clinically indicated.
Vital Signs: All patients on continuous sedative infusions require continuous monitoring of heart rate, blood pressure (ideally via arterial line), pulse oximetry (SpO₂), and end-tidal CO₂ (EtCO₂). Regularly verify the quality of invasive monitoring waveforms.
Laboratory Monitoring: Trend daily labs, including a complete blood count (CBC) and basic metabolic panel. An arterial blood gas (ABG) should be checked as needed for ventilator adjustments, and lactate levels should be trended to monitor perfusion.

Clinical Pearl: The Value of Capnography +

Early detection of a rising EtCO₂ in a mechanically ventilated patient can be the first sign of worsening respiratory mechanics, oversedation leading to reduced respiratory drive, or ventilator dyssynchrony. It allows for prompt adjustments before significant hypercarbia or acidemia develops.

7. Documentation and Quality Metrics

Utilizing integrated electronic health record (EHR) tools and tracking key performance indicators (KPIs) are essential for monitoring sedation practices, evaluating patient outcomes, and driving continuous quality improvement.

Electronic Flow Sheets: Document sedation scores, ventilator settings, vasopressor doses, and other key parameters in real time using integrated EHR flow sheets. This facilitates trend analysis and communication between shifts.
Key Performance Indicators (KPIs): Track unit-level metrics such as ventilator-free days, incidence of VTE, rates of stress ulcer bleeding, catheter-related infection rates (CLABSI/CAUTI), and the prevalence of delirium.
Continuous Improvement: Conduct monthly audits of protocol adherence (e.g., SAT/SBT, VTE prophylaxis). Use these data to provide targeted staff education and refine local guidelines.

Clinical Pearl: Transparent KPI Reporting +

Transparently reporting unit-level KPIs on a public dashboard or in staff meetings fosters a culture of accountability and has been shown to improve adherence to sedation, delirium, and prophylaxis protocols, ultimately improving patient outcomes.

References

Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
Hanidziar D, Bittner EA. Monitoring sedation in mechanically ventilated patients: a narrative review. Crit Care. 2022;26(1):180.
Helms J, Severac F, Merdji H, et al. Thromboprophylaxis in critical care. Ann Intensive Care. 2022;12(1):107.
Khan A, Patel R, Kumar A, et al. Stress ulcer prophylaxis within the ICU. US Pharm. 2023;48(12):HS-5–HS-10.
Krishnamoorthy V, Lewis K, Patanwala AE, et al. The SCCM and ASHP guideline for the prevention and management of stress-related mucosal bleeding in critically ill adults. Crit Care Med. 2024;52(7):e1234–e1247.
Gitti N, Biondi-Zoccai G, De Luca L, et al. Optimal sedation strategies in the ICU. Front Med (Lausanne). 2022;9:901343.
VUMC SICU VTE Prophylaxis Guideline. Vanderbilt University Medical Center; 2023.
Seo Y, Lee YJ, Park S, et al. Korean Society of Critical Care Medicine (KSCCM) clinical practice guidelines for pain, agitation, and delirium in the intensive care unit. Acute Crit Care. 2022;37(1):1–27.
Kim YK, Lee H, Lee YJ, et al. Korean Society of Critical Care Medicine (KSCCM) clinical practice guidelines on intensive care unit sedation and sleep management. Acute Crit Care. 2022;37(1):1–38.

Objective